208 related articles for article (PubMed ID: 9237176)
1. HBME-1 immunostaining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma.
Sack MJ; Astengo-Osuna C; Lin BT; Battifora H; LiVolsi VA
Mod Pathol; 1997 Jul; 10(7):668-74. PubMed ID: 9237176
[TBL] [Abstract][Full Text] [Related]
2. The role of immunolocalization of CD57 and GLUT-1 in cell blocks in fine-needle aspiration diagnosis of papillary thyroid carcinoma.
Chandan VS; Faquin WC; Wilbur DC; Khurana KK
Cancer; 2006 Oct; 108(5):331-6. PubMed ID: 16944537
[TBL] [Abstract][Full Text] [Related]
3. Fine-needle aspiration biopsy of papillary thyroid carcinoma: diagnostic utility of cytokeratin 19 immunostaining.
Nasser SM; Pitman MB; Pilch BZ; Faquin WC
Cancer; 2000 Oct; 90(5):307-11. PubMed ID: 11038428
[TBL] [Abstract][Full Text] [Related]
4. HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma.
Nga ME; Lim GS; Soh CH; Kumarasinghe MP
Diagn Cytopathol; 2008 Aug; 36(8):550-6. PubMed ID: 18618720
[TBL] [Abstract][Full Text] [Related]
5. Immunostaining for thyroid transcription factor-1 on fine-needle aspiration specimens of lung tumors: a comparison of direct smears and cell block preparations.
Liu J; Farhood A
Cancer; 2004 Apr; 102(2):109-14. PubMed ID: 15098255
[TBL] [Abstract][Full Text] [Related]
6. HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma.
Ito Y; Yoshida H; Tomoda C; Miya A; Kobayashi K; Matsuzuka F; Kakudo K; Kuma K; Miyauchi A
Anticancer Res; 2005; 25(1A):179-82. PubMed ID: 15816536
[TBL] [Abstract][Full Text] [Related]
7. [HBME-1 immunostaining in thyroid pathology].
Rigau V; Martel B; Evrard C; Rousselot P; Galateau-Salle F
Ann Pathol; 2001 Feb; 21(1):15-20. PubMed ID: 11223556
[TBL] [Abstract][Full Text] [Related]
8. Applications of monoclonal antibodies in clinical cytology as exemplified by studies with monoclonal antibody B72.3. The George N. Papanicolaou award lecture.
Johnston WW
Acta Cytol; 1987; 31(5):537-56. PubMed ID: 3314301
[TBL] [Abstract][Full Text] [Related]
9. Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.
Saggiorato E; De Pompa R; Volante M; Cappia S; Arecco F; Dei Tos AP; Orlandi F; Papotti M
Endocr Relat Cancer; 2005 Jun; 12(2):305-17. PubMed ID: 15947105
[TBL] [Abstract][Full Text] [Related]
10. Galectin-3 is not useful in thyroid FNA.
Mills LJ; Poller DN; Yiangou C
Cytopathology; 2005 Jun; 16(3):132-8. PubMed ID: 15924608
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.
de Matos PS; Ferreira AP; de Oliveira Facuri F; Assumpção LV; Metze K; Ward LS
Histopathology; 2005 Oct; 47(4):391-401. PubMed ID: 16178894
[TBL] [Abstract][Full Text] [Related]
12. Galectin-3 is highly expressed in nonencapsulated papillary thyroid carcinoma but weakly expressed in encapsulated type; comparison with Hector Battifora mesothelial cell 1 immunoreactivity.
Torregrossa L; Faviana P; Camacci T; Materazzi G; Berti P; Minuto M; Elisei R; Vitti P; Miccoli P; Basolo F
Hum Pathol; 2007 Oct; 38(10):1482-8. PubMed ID: 17597183
[TBL] [Abstract][Full Text] [Related]
13. Estimation of hormone receptor status in fine-needle aspirates and paraffin-embedded sections from breast cancer using the novel rabbit monoclonal antibodies SP1 and SP2.
Cano G; Milanezi F; Leitão D; Ricardo S; Brito MJ; Schmitt FC
Diagn Cytopathol; 2003 Oct; 29(4):207-11. PubMed ID: 14506673
[TBL] [Abstract][Full Text] [Related]
14. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms.
Inohara H; Honjo Y; Yoshii T; Akahani S; Yoshida J; Hattori K; Okamoto S; Sawada T; Raz A; Kubo T
Cancer; 1999 Jun; 85(11):2475-84. PubMed ID: 10357421
[TBL] [Abstract][Full Text] [Related]
15. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions.
Mataraci EA; Ozgüven BY; Kabukçuoglu F
Pol J Pathol; 2012 Mar; 63(1):58-64. PubMed ID: 22535608
[TBL] [Abstract][Full Text] [Related]
16. HBME-1 and CD15 immunocytochemistry in the follicular variant of thyroid papillary carcinoma.
Ohta M; Ookoshi T; Naiki H; Imamura Y
Pathol Int; 2015 Mar; 65(3):119-25. PubMed ID: 25597783
[TBL] [Abstract][Full Text] [Related]
17. Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms.
Aron M; Kapila K; Verma K
Indian J Pathol Microbiol; 2006 Jul; 49(3):376-80. PubMed ID: 17001889
[TBL] [Abstract][Full Text] [Related]
18. Application of the immunoperoxidase technique to cell block preparations from fine needle aspirates.
Kung IT; Chan SK; Lo ES
Acta Cytol; 1990; 34(3):297-303. PubMed ID: 2160769
[TBL] [Abstract][Full Text] [Related]
19. Retinoblastoma expression in thyroid neoplasms.
Anwar F; Emond MJ; Schmidt RA; Hwang HC; Bronner MP
Mod Pathol; 2000 May; 13(5):562-9. PubMed ID: 10824929
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic characterization of lung cancers in fine needle aspiration biopsies using monoclonal antibody B72.3.
Johnston WW; Szpak CA; Thor A; Schlom J
Cancer Res; 1986 Dec; 46(12 Pt 1):6462-70. PubMed ID: 3022920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
